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Abstract: Background - Methoxyflurane was used as an anaesthetic agent from 1958 until it was 
withdrawn around 1974 after dose-related patient nephrotoxicity was identified. It is now available only 
for administration via the Medical Developments International Penthrox Inhaler device for analgesia. 
When administering methoxyflurane, ambulance officers will be exposed to some methoxyflurane 
vapour. A previous study has extrapolated data from anaesthetized patients to suggest that such 
occupational exposure is within safe limits. There is a need to explore the robustness of these thresholds. 
Approach – A model is created to investigate the range of possible regression lines from repeated 
bootstrap samples of the same patient data, and to describe the probability distribution of those regression 
lines. Findings – The model shows a wide range of possible extrapolations due to the limited patient data 
set and the extrapolation being conducted over 2 - 5 orders of magnitude of exposure. With the range of 
ambulance officer exposures reported elsewhere, 95.7% of these regressions fall within an identified safe 
limit, suggesting that one-off exposures of this nature are safe. This model does not account for repeated 
exposures over days or weeks as would be seen in occupational settings. Originality – Bootstrapping 
methods are applied to test the statistical robustness of extrapolation. Results indicate that ambulance 
crews could be safe if exposed between the limits currently in place. 
Keywords: Identification and validation; Clinical validation; Healthcare management; Physiological 
models; Physiology; Parameter identification; Health and safety. 

1. INTRODUCTION 
Methoxyflurane is a fluorinated hydrocarbon that was used as 
an anaesthetic agent from 1958, and was once considered 
suitable for “any patient and any operation” (Van Poznak, 
1972). Early adopters of methoxyflurane noted cardiac 
stability, stable sedation and unconsciousness, low 
irritability, and a gradual return to consciousness. A noted 
issue was the slow induction of anaesthesia (Thomason, 
Light & Holaday, 1962). By 1968 methoxyflurane made up 
10% of annual purchases of inhaled anaesthetics in the USA 
(Van Poznak, 1972). In later years, however, methoxyflurane 
was noted to cause post anaesthetic high output renal failure 
which was sometimes transient but occasionally remained for 
12 months or more (Crandell, Pappas & Macdonald, 1966). 
The cause of patient nephrotoxicity was identified as being 
primarily due to fluoride ions, a metabolite of 
methoxyflurane (Cousins & Mazze, 1972). 
At around the same time, Corbett and Ball (1971) also 
identified exposure to methoxyflurane vapour as a possible 
occupational hazard. Operating room vapour inhaled by the 
anaesthetist ranged from 1.3ppm to 9.8ppm, and resulted in 
methoxyflurane being detectable on the anaesthetist‟s breath 
for 12 to 30 hours depending also on the duration of surgery 
attended. Additionally, there was an up to fivefold increase in 
fluoride ions in the anaesthetist‟s urine following exposure. 
This appears to be the sole study of biological markers 
following occupational exposure. 
Methoxyflurane was also used in lower doses as an analgesic 
agent. From 1968, Abbott Laboratories (Chicago, IL, USA) 
manufactured the Penthrane Analgizer
®
 for managing the 
pain of labour and short medical procedures (Coffey et al., 
2014). Abbott Laboratories later refined the device as the 
Penhalor
®
, and Cyprane Ltd. (Keighley, UK) manufactured 
the Cardiff Penthrane Inhaler
®
 for the same purpose. Two 
studies utilising these devices failed to find indications of 
nephrotoxicity in patients when methoxyflurane was used in 
analgesic doses (Artusio et al., 1971; Rosen, Latto & 
Asscher, 1972). 
From 1958 to 1974, a total of ~100 cases of postoperative 
nephrotoxicity due to anaesthetic administration of 
methoxyflurane were reported, with approximately ~20 
attributable patient deaths (Mazze, 2006). Methoxyflurane 
use for both anaesthesia and analgesia was discontinued in 
the USA in 1974 (Dayan, 2015) and in the UK at a similar 
time (Fletcher, 2015). As a result of methoxyflurane falling 
out of favour, there is a significant paucity of safety research 
since the 1970s until fairly recently. 
In contrast, Medical Developments International, then 
Medical Developments Australia (Scoresby, Victoria, 
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1. I T TI  
ethoxyflurane is a fluorinated hydrocarbon that as used as 
an anaesthetic agent fro  1958, and as once considered 
suitable for “any patient and any operation” ( an Poznak, 
1972). Early adopters of ethoxyflurane noted cardiac 
stability, stable sedation and unconsciousness, lo  
irritability, and a gradual return to consciousness.  noted 
issue as the slo  induction of anaesthesia (Tho ason, 
Light  oladay, 1962). y 1968 ethoxyflurane ade up 
10  of annual purchases of inhaled anaesthetics in the S  
( an Poznak, 1972). In later years, ho ever, ethoxyflurane 
as noted to cause post anaesthetic high output renal failure 
hich as so eti es transient but occasionally re ained for 
12 onths or ore ( randell, Pappas  acdonald, 1966). 
The cause of patient nephrotoxicity as identified as being 
pri arily due to fluoride ions, a etabolite of 
ethoxyflurane ( ousins  azze, 1972). 
t around the sa e ti e, orbett and all (1971) also 
identified exposure to ethoxyflurane vapour as a possible 
occupational hazard. perating roo  vapour inhaled by the 
anaesthetist ranged fro  1.3pp  to 9.8pp , and resulted in 
ethoxyflurane being detectable on the anaesthetist‟s breath 
for 12 to 30 hours depending also on the duration of surgery 
attended. dditionally, there as an up to fivefold increase in 
fluoride ions in the anaesthetist‟s urine follo ing exposure. 
This appears to be the sole study of biological arkers 
follo ing occupational exposure. 
ethoxyflurane as also used in lo er doses as an analgesic 
agent. Fro  1968, bbott Laboratories ( hicago, IL, S ) 
anufactured the Penthrane nalgizer
®
 for anaging the 
pain of labour and short edical procedures ( offey et al., 
2014). bbott Laboratories later refined the device as the 
Penhalor
®
, and yprane Ltd. ( eighley, ) anufactured 
the ardiff Penthrane Inhaler
®
 for the sa e purpose. T o 
studies utilising these devices failed to find indications of 
nephrotoxicity in patients hen ethoxyflurane as used in 
analgesic doses ( rtusio et al., 1971; osen, Latto  
sscher, 1972). 
Fro  1958 to 1974, a total of ~100 cases of postoperative 
nephrotoxicity due to anaesthetic ad inistration of 
ethoxyflurane ere reported, ith approxi ately ~20 
attributable patient deaths ( azze, 2006). ethoxyflurane 
use for both anaesthesia and analgesia as discontinued in 
the S  in 1974 ( ayan, 2015) and in the  at a si ilar 
ti e (Fletcher, 2015). s a result of ethoxyflurane falling 
out of favour, there is a significant paucity of safety research 
since the 1970s until fairly recently. 
In contrast, edical evelop ents International, then 
edical evelop ents ustralia (Scoresby, ictoria, 
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1. INTRODUCTION 
Methoxy lurane is a fluorinated h drocarbon that was used as
an anaesthetic gen  from 1958, and w s once considered
uitable for “any patien  and y operation” (Van Poznak,
1972). Early adopters of methoxyflurane oted cardiac
stability, stable sedation and unconsciousness, l w
irritability, an  a gradual return to consciousness. A noted
issue w s the slow induction of aest es a (Thomason,
Light & Holaday, 1962). By 1968 methoxyflurane made up
10% of annual purcha es of in aled anaesthetics in the USA
(Van Poznak, 1972). In later years, however, methoxyflurane
was noted t  cause post anaesthetic high output renal failure
w ich was sometimes transient but occ ionally r m ined for
12 months or more (Crandell, Pappa  & Macdonald, 1966).
The cause of patient nephrotoxicity was identified as being 
primarily due to fluoride ions, a metabolite of 
methoxyflurane (Cousins & Mazze, 1972). 
At around the same time, Co bett and Ball (1971) also
identifi d exposure to ethoxyflurane vapour as a possible
occupational hazard. Operating r om vapour inhaled y the
anaesthetist ranged from 1.3ppm t  9.8ppm, and resulted in
methoxyflurane being detectable on the anaesthetist‟s breath
or 12 to 30 hours depending also on the duration of surgery
attended. Additionally, there was an up to fivefold increase in 
fluoride ions in the anaesthetist‟s urine following exposure. 
This appears to be the sole study of biological markers 
following occupational exposure. 
Methoxyflurane was also us d in lower doses as  analgesic
age t. From 1968, Abbott Laboratories (Chicag , IL, USA)
manufactured the Penthrane Analgizer
®
 for managing
pain of labour and short medical procedures (Coffey et al.,
2014). Abbott Laboratories later efined th device as the
Penhalor
®
, and Cyprane Ltd. (Keighley, UK) manufactured
the Cardiff Penthrane Inhaler
®
 for the same purpose. Two
studies utilising these devices failed to find indications of
nephrotoxicity in patients when methoxyflurane was used in 
analgesic doses (Artusio et al., 1971; Rosen, Latto & 
Asscher, 1972). 
From 1958 to 1974, a total of ~100 cases of postoperative
nephrotoxicity due to anaesthetic administration of
m th xyflurane wer  reported, with approxima ely ~20
attributable patient deaths (Mazze, 2006). Methoxyflurane
use for bot  anaesthesia and analgesia was discontinued in
the USA in 1974 (Dayan, 2015) and in the UK at a similar
time (Fletcher, 2015). As a r su t of methoxyflurane falling 
out of favour, there is a significant paucity of safety research 
since the 1970s until fairly recently. 
In contrast, Medical Developments International, then 
Medical Developments Australia (Scoresby, Victoria, 
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Australia) has been manufacturing an analgesic 
methoxyflurane device called Penthrox
®
 from 1978 through 
to present day (Dayan, 2015). The Penthrox inhaler is similar 
in appearance to the Analgizer, and is a simple device shaped 
like a whistle (Dayan, 2016). This device features a „dilution 
hole‟ which allows the patient to control the concentration of 
methoxyflurane delivered to them: 0.2% to 0.4% with the 
dilution hole open, and 0.5% to 0.7% with the hole closed 
(Medsafe, 2013). The manufacturer reports that Penthrox has 
been used by about 2.5 to 3 million patients in Australia and 
New Zealand (Dayan, 2015). Two recent studies have failed 
to find signs of nephrotoxicity in patients administered 
Penthrox (Jacobs, 2010; Coffey et al., 2014). However both 
studies received funding from the manufacturer, raising the 
possibility of bias. 
At the present time Penthrox is widely used by ambulance 
services across Australia, and is the typical analgesic agent 
for use by less qualified staff (ACT Ambulance Service, 
2012; Ambulance Victoria, 2015; Ambulance Service NSW, 
2011; Queensland Ambulance Service, 2016; St. John NT, 
2013). This widespread and on-going use of methoxyflurane 
with no reported adverse events implies occupational safety 
(Therapeutic Goods Administration, 2014). Most Australian 
ambulance services implement a strategy to reduce 
occupational exposure, such as limiting the number of doses 
that can be given in an ambulance (Ambulance Service NSW, 
2011), or encouraging use of adequate ventilation and the use 
of a proprietary charcoal filter attached to the device (St. John 
NT, 2013). It is possible that these mitigating measures are 
responsible for a lack of adverse occupational events. 
However, the contribution of these measures to reductions in 
methoxyflurane exposure has not been reported and remains 
ambiguous. 
Methoxyflurane is currently utilised in the New Zealand 
ambulance setting (St. John NZ, 2013). Given a recent 
Cochrane review‟s finding that flurane derivatives such as 
methoxyflurane are suitable analgesics (Klomp et al., 2012), 
wider uptake of methoxyflurane is possible and re-evaluation 
of occupational safety is warranted.  
Frangos et al. (2016) was sponsored by the Penthrox 
manufacturer to develop a computational model of 
methoxyflurane vapour exposure in an ambulance, and 
compared this model to an extrapolation of data from 
anaesthetised patients to confirm occupational safety. They 
concluded the degree ambulance crews were exposed to 
methoxyflurane was safe. However, the findings were 
dependent on the extrapolation of limited data. Those authors 
applied a high degree of extrapolation using simple linear 
assumptions. It is worth re-evaluating the validity of the 
findings by applying alternative extrapolation methods.  
This paper re-evaluates the findings of Frangos et al. (2016) 
using a bootstrapping method with alternative extrapolation 
functions to yield a more statistically defensible risk 
assessment. 
2. METHODS 
2.1  Data 
Data from 18 male patients that underwent methoxyflurane 
anaesthesia for surgery were used in this study (Cousins and 
Mazze, 1973), and are re-evaluated here. In the original study 
the anaesthesia was performed at Veterans Administration 
Hospital (Palo Alto, CA, USA). The patients were 
randomized to receive either 0.5, 1.0 or 1.5 MAC of 
methoxyflurane, and total anaesthetic dose for each patient 
was reported as a concentration-duration composite: MAC 
hours. Post-operative serum fluoride levels were monitored 
and peak values reported. Table 1 and Figure 1 (left) show 
the measured values for each patient. Methoxyflurane 
exposure is converted to the concentration-duration 
composite with units of thousands of parts-per-million (ppm) 
minutes, using MAC = 0.16% (Cousins and Mazze, 1973). 
Patient toxicity identification (as „none‟, „subclinical‟, „mild‟, 
or „toxic‟) is reproduced from the original study. 
  
Figure 1: Distribution of serum fluoride vs exposure in MAC hours (left), ROC curves for toxicity as a function of exposure in 
MAC hours (centre), or serum fluoride (right) 
 
MAC hours 
MAC hours -> toxicity 
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Table 1: Dose-peak response data from Cousins and Mazze 
(1973), extracted from graphical presentation using the 










1 1 96.0 21 None 
2 1.5 144.0 35 None 
3 2 192.0 30 None 
4 2.1 201.6 38 None 
5 2.6 249.6 37 None 
6 2.6 249.6 50 Mild 
7 2.6 249.6 95 Mild 
8 2.9 278.4 31 None 
9 2.9 248.4 40 None 
10 3 288.0 62 Subclinical 
11 3 288.0 70 Subclinical 
12 3 288.0 78 Subclinical 
13 4.5 432.0 98 None 
14 5 480.0 90 Mild 
15 5 480.0 115 Mild 
16 6.9 662.4 119 Toxic 
17 8.9 854.4 174 Toxic 
18 9 864.0 80 Toxic 
2.2  Model 
In the present analysis, two models were used to link 
exposure: 1000 ppm-mins (TPM) and serum fluoride (SF) 
data. We used a simple linear regression and a power law 
relationship, see Eq.1 and Eq.2 respectively. 
SF=x1TPM+x2   (1) 
SF=x3TPM
x4
   (2) 
Least-squares linear regression was used to 
determine x1 and x2 and least-squares linear regression of 
log(SF) and log(TPM) data was used to determine x3 and x4. 
A bootstrapping analysis was undertaken to determine the 
range of possible regression lines that could reasonably be 
expected by the models. Specifically 18 (TPM, SF) data pairs 
were randomly selected with replacement from Table 1. 
Linear regression was undertaken for both models to yield 
lines of best fit through the re-sampled data. This process was 
repeated 10,000 times yielding 10,000 parameter sets for 
each model. The cumulative probability of any such 
regression line occurring for a given level of methoxyflurane 
exposure was calculated. All analysis was undertaken on an 
Ubuntu 16.04 framework with GNU Octave 4.0.2 on an Intel 
Core 2 Duo 64-bit laptop with 4GB RAM. Results are shown 
in Figure 2. 
In plotting results, the green vertical lines illustrate the lowest 
ambulance crew exposure and the „worst case‟ ambulance 
exposure modelled by Frangos et al. (2016). The horizontal 
dashed magenta line illustrates serum fluoride of 40µmol/L. 
Peak serum fluoride data from Cousins and Mazze (1973) 
showed no patient suffered renal toxicity below 40µmol/L, 
suggesting this level may be non-toxic in the setting of 
methoxyflurane exposure. 
2.3  Estimated safety and exposure levels 
Figure 1 centre and right show that toxicity is sensitive to 
exposure and serum fluoride. Ranksum values were p=0.005, 
0.019 and 0.002 for the TPM score with respect to sub-
clinical, mild and clinical toxicity, respectively. Serum 
fluoride exhibited similar distinction across toxicity groups 
(0.002, 0.003, and 0.027, for sub-clinical, mild and clinical 
toxicity, respectively). Hence, both serum fluoride and 
exposure were indicators of toxicity risk. 
Paramedic methoxyflurane exposure has not been quantified 
in the workplace. Frangos et al. (2016) provided mean 
attendant exposure from 134 paramedics (0.11 thousand ppm 
minutes) but did not explicitly provide peak exposure levels – 
which is critical to occupational health. However, minimum 
and peak levels could be determined via the models provided 
by Frangos et al., with a range of 0.005 to 0.3 thousand ppm 
minutes implied. No corresponding fluoride levels were 
reported. 
Desmond (1974) observed 11 patients following anaesthesia 
with methoxyflurane doses ranging from 1.3 to 4.0 MAC 
hours, noting high-volume renal failure in the majority of 
patients. That author recommended an upper limit of 
methoxyflurane exposure of 2.5 MAC hours (240 TPM), 
although no statistical analysis was given to provide insight 
into how the figure was arrived at. 
3. RESULTS 
Bootstrapping analysis on regression models provides the 
level of certainty of extrapolation from the existing post-
anaesthesia patient dataset to paramedic exposure (Figure 2). 
The upper 95
th
 percentile regression line for the linear model 
(Figure 2 upper) closely followed the 40µmol/L serum 
fluoride level identified as an upper limit for safe exposure. 
The cumulative probability of serum fluoride curves for the 
reported minimum and maximum paramedic exposure were 
virtually indistinguishable for the linear model (Figure 3 
upper). This consistency in serum fluoride probability 
distribution occurred despite nearly 2 orders of magnitude 
across exposure levels. In contrast, the extrapolated power-
law model implied certain occupational safety in the 
extrapolated region (Figure 3 lower). 
The cumulative probability curve in the linear model for the 
2.5 MAC hours exposure limit suggested by Desmond (1974) 
fell almost entirely beyond the 40µmol/L safe fluoride limit 
(Figure 4). This finding implies that an exposure threshold 
2.5 MAC affords inadequate safety. 
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Table 1: Dose-peak response data from Cousins and Mazze 
(1973), extracted from graphical presentation using the 










1 1 96.0 21 None 
2 1.5 144.0 35 None 
3 2 192.0 30 None 
4 2.1 201.6 38 None 
5 2.6 249.6 37 None 
6 2.6 249.6 50 Mild 
7 2.6 249.6 95 Mild 
8 2.9 278.4 31 None 
9 2.9 248.4 40 None 
10 3 288.0 62 Subclinical 
11 3 288.0 70 Subclinical 
12 3 288.0 78 Subclinical 
13 4.5 432.0 98 None 
14 5 480.0 90 Mild 
15 5 480.0 115 Mild 
16 6.9 662.4 119 Toxic 
17 8.9 854.4 174 Toxic 
18 9 864.0 80 Toxic 
2.2  Model 
In the present analysis, two models were used to link 
exposure: 1000 ppm-mins (TPM) and serum fluoride (SF) 
data. We used a simple linear regression and a power law 
relationship, see Eq.1 and Eq.2 respectively. 
SF=x1TPM+x2   (1) 
SF=x3TPM
x4
   (2) 
Least-squares linear regression was used to 
determine x1 and x2 and least-squares linear regression of 
log(SF) and log(TPM) data was used to determine x3 and x4. 
A bootstrapping analysis was undertaken to determine the 
range of possible regression lines that could reasonably be 
expected by the models. Specifically 18 (TPM, SF) data pairs 
were randomly selected with replacement from Table 1. 
Linear regression was undertaken for both models to yield 
lines of best fit through the re-sampled data. This process was 
repeated 10,000 times yielding 10,000 parameter sets for 
each model. The cumulative probability of any such 
regression line occurring for a given level of methoxyflurane 
exposure was calculated. All analysis was undertaken on an 
Ubuntu 16.04 framework with GNU Octave 4.0.2 on an Intel 
Core 2 Duo 64-bit laptop with 4GB RAM. Results are shown 
in Figure 2. 
In plotting results, the green vertical lines illustrate the lowest 
ambulance crew exposure and the „worst case‟ ambulance 
exposure modelled by Frangos et al. (2016). The horizontal 
dashed magenta line illustrates serum fluoride of 40µmol/L. 
Peak serum fluoride data from Cousins and Mazze (1973) 
showed no patient suffered renal toxicity below 40µmol/L, 
suggesting this level may be non-toxic in the setting of 
methoxyflurane exposure. 
2.3  Estimated safety and exposure levels 
Figure 1 centre and right show that toxicity is sensitive to 
exposure and serum fluoride. Ranksum values were p=0.005, 
0.019 and 0.002 for the TPM score with respect to sub-
clinical, mild and clinical toxicity, respectively. Serum 
fluoride exhibited similar distinction across toxicity groups 
(0.002, 0.003, and 0.027, for sub-clinical, mild and clinical 
toxicity, respectively). Hence, both serum fluoride and 
exposure were indicators of toxicity risk. 
Paramedic methoxyflurane exposure has not been quantified 
in the workplace. Frangos et al. (2016) provided mean 
attendant exposure from 134 paramedics (0.11 thousand ppm 
minutes) but did not explicitly provide peak exposure levels – 
which is critical to occupational health. However, minimum 
and peak levels could be determined via the models provided 
by Frangos et al., with a range of 0.005 to 0.3 thousand ppm 
minutes implied. No corresponding fluoride levels were 
reported. 
Desmond (1974) observed 11 patients following anaesthesia 
with methoxyflurane doses ranging from 1.3 to 4.0 MAC 
hours, noting high-volume renal failure in the majority of 
patients. That author recommended an upper limit of 
methoxyflurane exposure of 2.5 MAC hours (240 TPM), 
although no statistical analysis was given to provide insight 
into how the figure was arrived at. 
3. RESULTS 
Bootstrapping analysis on regression models provides the 
level of certainty of extrapolation from the existing post-
anaesthesia patient dataset to paramedic exposure (Figure 2). 
The upper 95
th
 percentile regression line for the linear model 
(Figure 2 upper) closely followed the 40µmol/L serum 
fluoride level identified as an upper limit for safe exposure. 
The cumulative probability of serum fluoride curves for the 
reported minimum and maximum paramedic exposure were 
virtually indistinguishable for the linear model (Figure 3 
upper). This consistency in serum fluoride probability 
distribution occurred despite nearly 2 orders of magnitude 
across exposure levels. In contrast, the extrapolated power-
law model implied certain occupational safety in the 
extrapolated region (Figure 3 lower). 
The cumulative probability curve in the linear model for the 
2.5 MAC hours exposure limit suggested by Desmond (1974) 
fell almost entirely beyond the 40µmol/L safe fluoride limit 
(Figure 4). This finding implies that an exposure threshold 
2.5 MAC affords inadequate safety. 
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Figure 2: Regression of bootstrap samples from the linear and 
power law models of serum fluoride vs. methoxyflurane 
exposure data. 
4. DISCUSSION 
The bootstrap analysis of the linear model implied a wide 
range of possible serum fluoride levels in the occupational 
exposure region, compared with the single extrapolation 
proposed by Frangos et al. (2016). Note that the upper 5% 
likelihood threshold aligned with the clinically derived 
threshold for elevated risk for nephrotoxicity. In contrast, the 
power-law model implied much lower levels of serum 
fluoride due to occupational exposure. The cumulative 
probability curves for reported minimum and modelled 
maximum exposure show that 95.7% of linear regression 
lines from the data are below the 40µmol/L serum fluoride 
threshold. This result is reassuring, and mitigates some of the 
concern due to the range of possible regression lines. This 
finding suggests that ambulance crews will be safe if exposed 
between the limits described. 
The small cluster of data reduces the certainty of 
extrapolation beyond the range of the data cluster, hence the 
wide probability distribution for the linear model. The power 
law model retained a relatively consistent distribution 
compared to the linear model due to the constraint that it 
must pass through (0,0). This constraint on the power law 
means that the serum level due to exposure must always track 
to a low value at low exposure levels, even if clearance of 
fluoride is non-linear. 
 
 
Figure 3: Cumulative probability curves for the purported 
minimum and maximum limits of exposure for linear (top) 
and power law (bottom) models. In the linear model the 
curves are so similar as to be indistinguishable. 
 
 
Figure 4: Cumulative probability curve for 2.5 MAC hours 
exposure in the linear model. 
The exposure for anaesthetised patients (Cousins and Mazze, 
1973) is 2 - 5 orders of magnitude greater than the proposed 
exposure of ambulance officers (Frangos et al., 2016). In the 
absence of low-exposure data, there is no reason to believe 
that either a linear or a power law model is more 
representative of the serum fluoride levels caused by 
exposure to methoxyflurane. In particular, a linear model 
could be possible even when the serum intercept is below 
zero. In such cases, the low dose may not be absorbed by the 
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lung and there would be no peak serum fluoride at all. In 
contrast, a positive serum fluoride level intercept may occur 
due to environmental fluoride intake (i.e. fluoridated water, 
some foods). In contrast, the power-law model may be 
appropriate when methoxyflurane or fluoride excretion 
curves are considered (Corbett and Ball, 1971). 
A number of significant questions remain unaddressed. The 
data used to identify the „minimum paramedic exposure‟ was 
from a secondary source, and its accuracy has not been 
confirmed. Ambulance officer qualification could affect 
methoxyflurane exposure, as higher-qualified officers have a 
wider range of analgesia options (Ambulance Victoria, 2015; 
St. John NT). The „maximum paramedic exposure‟ modelling 
in Frangos et al. (2016) assumes that the ambulance is mobile 
and that air conditioning systems are activated, which is not 
truly a worst case scenario. 
Accumulation could occur in occupational use where the 
ambulance officer is exposed on subsequent days or weeks. 
There is potential for greater and greater accumulation of 
methoxyflurane in tissue and for subsequent increased 
fluoride levels with re-exposure, and this needs to be further 
investigated. Hence, it is possible that this analysis yields risk 
prediction that is relevant only to single dose scenarios, and 
fluoride ion accumulation may significantly increase the 
occupational risk. 
Some medications alter the risk profile of methoxyflurane. 
Churchill (1976) describes a patient whose serum fluoride 
was significantly higher than expected after 90 minutes‟ 
exposure to 0.16% methoxyflurane (114µmol/L after 144 
TPM). This was identified as likely due to the patient having 
previously ingested a drug (secobarbital) which increased 
methoxyflurane metabolism. Additionally, nephrotoxicity 
appears to be altered in exposed persons simultaneously 
taking nephrotoxic medications such as tetracycline (Proctor, 
1971; Cousins and Mazze, 1972). 
Ambulance officers are at risk of interactions between 
occupationally absorbed methoxyflurane and personal 
concomitant use either of medications that increase 
methoxyflurane metabolism or of other nephrotoxic 
medications, although the effect of these interactions with 
occupationally exposed levels is unknown. 
This model has demonstrated the high degree of uncertainty 
with regards to serum fluoride and therefore of nephrotoxic 
risk to those occupationally exposed to methoxyflurane. 
There is a need to obtain further data in order to more 
accurately assess that risk. As anaesthetic toxicity has been 
demonstrated, the anaesthetic data set will never be expanded 
to improve extrapolation. Therefore further research is 
needed which directly measures the serum fluoride of those 
who are exposed in specific occupational environments. 
5. CONCLUSIONS 
The occupational risk of methoxyflurane remains ambiguous 
despite its sustained use in analgesia. This research has 
shown that previous attempts to verify the occupational 
safety of attendant ambulance officers have been incomplete 
and did not conclusively determine the risk. In order to fully 
appraise the occupational risk of methoxyflurane, low dose 
vs. serum fluoride data must be taken and the characteristics 
of fluoride accumulation in ambulance staff must be assessed. 
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lung and there would be no peak serum fluoride at all. In 
contrast, a positive serum fluoride level intercept may occur 
due to environmental fluoride intake (i.e. fluoridated water, 
some foods). In contrast, the power-law model may be 
appropriate when methoxyflurane or fluoride excretion 
curves are considered (Corbett and Ball, 1971). 
A number of significant questions remain unaddressed. The 
data used to identify the „minimum paramedic exposure‟ was 
from a secondary source, and its accuracy has not been 
confirmed. Ambulance officer qualification could affect 
methoxyflurane exposure, as higher-qualified officers have a 
wider range of analgesia options (Ambulance Victoria, 2015; 
St. John NT). The „maximum paramedic exposure‟ modelling 
in Frangos et al. (2016) assumes that the ambulance is mobile 
and that air conditioning systems are activated, which is not 
truly a worst case scenario. 
Accumulation could occur in occupational use where the 
ambulance officer is exposed on subsequent days or weeks. 
There is potential for greater and greater accumulation of 
methoxyflurane in tissue and for subsequent increased 
fluoride levels with re-exposure, and this needs to be further 
investigated. Hence, it is possible that this analysis yields risk 
prediction that is relevant only to single dose scenarios, and 
fluoride ion accumulation may significantly increase the 
occupational risk. 
Some medications alter the risk profile of methoxyflurane. 
Churchill (1976) describes a patient whose serum fluoride 
was significantly higher than expected after 90 minutes‟ 
exposure to 0.16% methoxyflurane (114µmol/L after 144 
TPM). This was identified as likely due to the patient having 
previously ingested a drug (secobarbital) which increased 
methoxyflurane metabolism. Additionally, nephrotoxicity 
appears to be altered in exposed persons simultaneously 
taking nephrotoxic medications such as tetracycline (Proctor, 
1971; Cousins and Mazze, 1972). 
Ambulance officers are at risk of interactions between 
occupationally absorbed methoxyflurane and personal 
concomitant use either of medications that increase 
methoxyflurane metabolism or of other nephrotoxic 
medications, although the effect of these interactions with 
occupationally exposed levels is unknown. 
This model has demonstrated the high degree of uncertainty 
with regards to serum fluoride and therefore of nephrotoxic 
risk to those occupationally exposed to methoxyflurane. 
There is a need to obtain further data in order to more 
accurately assess that risk. As anaesthetic toxicity has been 
demonstrated, the anaesthetic data set will never be expanded 
to improve extrapolation. Therefore further research is 
needed which directly measures the serum fluoride of those 
who are exposed in specific occupational environments. 
5. CONCLUSIONS 
The occupational risk of methoxyflurane remains ambiguous 
despite its sustained use in analgesia. This research has 
shown that previous attempts to verify the occupational 
safety of attendant ambulance officers have been incomplete 
and did not conclusively determine the risk. In order to fully 
appraise the occupational risk of methoxyflurane, low dose 
vs. serum fluoride data must be taken and the characteristics 
of fluoride accumulation in ambulance staff must be assessed. 
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